Invented and founded by Tess Fries, Elixira is a next-generation, patent-pending, AI-guided nanobot platform designed as a one-time injection for lifelong, autonomous prevention across all cancer types. Its technical feasibility has been independently confirmed by a leading Contract Research Organization (CRO), and all core technologies underlyingElixira have been peer-reviewed and validated. A detailed technical feasibility report is available to prospective partners under NDA.
Developed on in vivo–proven nanotechnology and biomedical engineering principles, Elixira integrates self-sustaining energy systems and multiple elimination methods to enable a proactive, continuous prevention model. Operating autonomously inside the human body, it detects, targets, and neutralizes cancer cells in real time — powered entirely by its own renewable energy systems.

Engineered for global scalability, ethical accessibility, and minimal infrastructure requirements, Elixira’s mission is to advance preventive cancer care worldwide — enabling earlier detection, intervention, and improved long-term health outcomes.

Biotechnology

Health Care

Life Sciences

Medical Devices

Nanotechnology

Technology

Elixira

The Lund office focuses on innovation and entrepreneurship, fostering new ideas in the biotechnology sector.

People (1)

Jobs (0)

Other offices